Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Non-Current Assets (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 3 years of Other Non-Current Assets data on record, last reported at $27.0 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 30.77% year-over-year to $27.0 million; the TTM value through Dec 2025 reached $27.0 million, down 30.77%, while the annual FY2025 figure was $27.0 million, 30.77% down from the prior year.
  • Other Non-Current Assets reached $27.0 million in Q4 2025 per INDV's latest filing, down from $39.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $39.0 million in Q4 2024 and bottomed at $27.0 million in Q4 2025.
  • Average Other Non-Current Assets over 3 years is $35.2 million, with a median of $37.5 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: grew 8.33% in 2024, then plummeted 30.77% in 2025.
  • A 3-year view of Other Non-Current Assets shows it stood at $36.0 million in 2023, then grew by 8.33% to $39.0 million in 2024, then tumbled by 30.77% to $27.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $27.0 million in Q4 2025, $39.0 million in Q1 2025, and $39.0 million in Q4 2024.